RARE Ultragenyx Pharmaceutical Inc.

59.52
-0.72  -1%
Previous Close 60.24
Open 60.68
Price To Book 3.86
Market Cap 3,420,761,652
Shares 57,472,474
Volume 290,581
Short Ratio
Av. Daily Volume 460,178

NewsSee all news

  1. Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
  2. Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
  3. Here’s What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE)
  4. Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
  5. See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 third cohort data due mid-2019.
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Approved under priority review November 15, 2017.
MEPSEVII (vestronidase alfa)
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 data released October 26, 2018 - endpoints not met.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data released August 22, 2017 - endpoints not met.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Approval announced April 17, 2018.
Crysvita (Burosumab)
X-Linked Hypophosphatemia (XLH)
Data released September 2018.
KRN23 Burosumab
Tumor-induced osteomalacia (TIO)
NDA to be filed mid-2019.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
sBLA filing for children due 2H 2019.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
Phase 1/2 data from second cohort due mid-2019.
DTX401
GSD1

Latest News

  1. Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
  2. Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
  3. Here’s What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE)
  4. Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
  5. See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
  6. Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer
  7. 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
  8. Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?
  9. Ultragenyx to Present at Upcoming Investor Conferences
  10. Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award
  11. Is Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Paid At A Competitive Rate?
  12. Edited Transcript of RARE earnings conference call or presentation 6-May-19 9:00pm GMT
  13. Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
  14. Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
  15. Ultragenyx Pharmaceutical Inc (RARE) Q1 2019 Earnings Call Transcript
  16. Ultragenyx: 1Q Earnings Snapshot
  17. Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
  18. What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?